SaniSure relocating from Oxnard to Camarillo
Medical device manufacturer SaniSure leased 32,000 square feet of industrial and office space at 1230 Calle Suerte in Camarillo. SaniSure is relocating its Oxnard operations to the NEFF Headwear property in Camarillo, CBRE said. “This building is a perfect fit for a company like SaniSure,” CBRE’s Jim Meaney said in a news release. “Ventura County Read More →
Sientra finds new factory to make breast implants
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Abbvie sues Amgen to block sales of Humira biosimilar
Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →
CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar
CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →
Amgen buying rights to Advaxis cancer treatment
Thousand Oaks-based biotech giant Amgen said it will buy the rights to develop and commercialize a cancer immunotherapy treatment Aug. 2. Under the agreement, Amgen will pay Princeton, N.J.-based Advaxis $40 million and buy $25 million worth of Advaxis common stock for the rights to develop and commercialize a preclinical cancer immunotherapy, which is designed Read More →
Tax measures could alter tri-county marijuana market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reports revenue increase in second quarter earnings
Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →
